SCHEMBL7909164

SCHEMBL7909164

C[C@H](NC(=O)C1(c2ccccc2)CCN(C(=O)c2ccc(-c3ccccc3)cc2)CC1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.50
ATM Q13315 1/20 0.49
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
FASN P49327 4/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
HPGD P15428 2/20 0.48
MAPK1 P28482 1/20 0.48
TSHR P16473 3/20 0.47
ALOX15 P16050 1/20 0.47
FNTA P49354 2/20 0.46
FNTB P49356 1/20 0.46
ALDH1A1 P00352 3/20 0.45
MAPT P10636 1/20 0.45
PGGT1B P53609 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13092229 0.95 CA12 (0.48) POLBATMCA12CA1CA2
SCHEMBL3714839 0.94 NPC1 (0.49) POLBATMCA12CA1CA2
SCHEMBL13092237 0.94 CA12 (0.47) POLBATMCA12CA1CA2
SCHEMBL13092174 0.93 MAPK1 (0.56) POLBATMCA12CA1CA2
SCHEMBL378834 0.92 TACR1 (0.48) POLBATMCA12CA1CA2
SCHEMBL13092230 0.91 CA12 (0.44) POLBATMCA12CA1CA2
SCHEMBL13092220 0.91 MKNK1 (0.50) POLBATMMAPK1ALDH1A1SMN1; SMN2
SCHEMBL13092221 0.91 PIN1 (0.47) POLBATMCA12CA1CA2
SCHEMBL13092211 0.91 TSHR (0.44) POLBATMCA12CA1CA2
SCHEMBL13092173 0.91 TACR1 (0.48) POLBATMCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 POLB 2329/4885ATM 2243/4885CA12 4882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.